Digital Pathology & Imaging - software & AI news

Daily news on software, AI, and companies shaping digital pathology & imaging.

Showing 301 results
Press release cover image

Oct 6, 2026

ZEISS demonstrates new digital and visual enhancements across ophthalmic workflows at AAO

ZEISS Medical Technology will showcase its latest innovations and digital technologies at AAO, including:Connected cataract workflow –ZEISS VERACITY Surgery Planner reaches 3 million surgical cases planned through cloud-based software, supporting surgical efficiency built on automation and accurate data.Excellent surgical ergonomics – The HMDmd CR3 head-mounted 3D digital display technology supports surgical visualization with excellent ergonomics across surgical workflows.Celebrating 1 million
Press release cover image

Oct 6, 2026

Spectral AI Submits New Technology Add-On Payment (NTAP) Application for DeepView™ System

DALLAS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the submission of a New Technology Add-On Payment (NTAP) application to the Centers for Medicare & Medicaid Services (CMS) for its DeepView™ System utilizing the alternative pathway. The NTAP program is designed to provide an addition
Press release cover image

Oct 5, 2026

AIRS Medical Receives FDA 510(k) Clearance for SwiftSight® Body Composition

AI-powered quantitative MRI solution enables imaging organizations to standardize body composition analysis, expand existing MRI services and create new revenue opportunitiesCHICAGO, Oct. 5, 2026 /PRNewswire/ -- AIRS Medical today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for SwiftSight® Body Composition, expanding the company's quantitative MRI platform into body composition analysis. SimonMed Imaging will be the first customer to deploy the newly c
A biopsy sample on a microscope slide in a lab setting.

Oct 3, 2026

CellCarta and Imagene AI expand CDx collaboration

CellCarta and Imagene AI have announced an enhanced collaboration aimed at streamlining the development and deployment of AI-driven biomarker and companion diagnostic programs for biopharma companies.This partnership focuses on a comprehensive approach that encompasses the entire lifecycle of biomarker programs, from initial strategy and assay development to validation, clinical trials, and regulatory compliance. Currently, they are collaborating on projects with two major pharmaceutical firms,
A mammogram film on a clinical table in a softly lit examination room.

Oct 2, 2026

Everlywell rolls out Clairity AI for breast cancer in US

Everlywell has introduced Clairity AI, a groundbreaking tool for assessing breast cancer risk from routine mammograms, marking a significant advancement in digital health.This launch coincides with Breast Cancer Awareness Month, enhancing the accessibility of Clairity Breast, the first FDA-authorized AI to evaluate a woman's five-year risk of developing breast cancer based on mammography screenings. The collaboration between Everlywell, led by Julia Cheek, and Clairity, founded by Dr. Connie Leh
Close-up of a biomarker assay with a microscope in a lab setting.

Oct 1, 2026

CellCarta, Imagene AI Broaden Ties on AI Biomarkers, Companion Diagnostics

CellCarta and Imagene AI have announced an enhanced partnership aimed at streamlining AI-driven biomarker and companion diagnostic (CDx) programs for biopharma companies, with active projects already in progress with two leading global pharmaceutical firms.This collaboration focuses on guiding projects from initial biomarker strategy through to clinical trial execution and regulatory approval. By integrating Imagene AI’s advanced assay development and biomarker prediction technologies with CellC
Press release cover image

Oct 1, 2026

Brainomix Announces New Phase III INBUILD® Data Highlighting Potential of Quantitative CT to Predict Disease Progression and Assess Treatment Response in Progressive Pulmonary Fibrosis

Published in the American Journal of Respiratory & Critical Care Medicine (AJRCCM), the analysis of 474 patients from Boehringer Ingelheim's Phase III INBUILD® HRCT sub-study represents the largest prospective evaluation of quantitative CT in patients with progressive pulmonary fibrosis (PPF) to date.Researchers used Brainomix e-Lung to assess quantitative CT measures. They found that these measures were sensitive to the effects of nintedanib from baseline to 24 weeks and 52 weeks, and assoc
Press release cover image

Oct 1, 2026

PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis

Companies to use AI-enabled digital pathology and spatial single-fiber analysis to characterize the mechanistic effects of MTX-474 in systemic sclerosis PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collabo
Press release cover image

Sep 30, 2026

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-free survival (RFS) of 99.6% Separate ePoster shows DecisionDx-Melanoma identifies early-stage, transected melanomas with recurrence risk similar to that seen in stage IIB disease, supporting closer surveillance when staging is uncertainFRIENDSWOOD, Texas, Sept. 30, 2026 /PRNewswire/ -- Castle Biosci
Press release cover image

Sep 30, 2026

AI Tool Finds and Fixes Training Gaps for Radiology Residents

Precision Education Promises to Fill Gap in FieldNEW YORK, Sept. 30, 2026 /PRNewswire/ -- A new study showed that using artificial intelligence to track which pathologies radiology residents saw each day made it possible to identify gaps in their clinical exposure and provide supplemental, targeted teaching cases. This approach helped ensure that residents were exposed to the full breadth of pathology needed for training, the study authors said.Led by NYU Langone Health researchers, the study ad
Minimalist heart silhouette representing healthcare

Sep 30, 2026

European Hospital Accelerate AI Medical Innovations with KAYTUS MotusAI Empowering Breakthroughs in Healthcare Computing Challenges

A European hospital has partnered with KAYTUS to enhance its AI capabilities through the implementation of the MotusAI platform, aiming to revolutionize healthcare delivery and operational efficiency.The collaboration focuses on creating a robust AI infrastructure that supports various applications, including diagnostic imaging and clinical assistants. This initiative is part of the hospital's broader strategy to evolve into a smart healthcare facility, leveraging AI to optimize workflows and im
Press release cover image

Sep 30, 2026

Medical Image Analysis Software Market to Reach US$ 6.3 Bn by 2031, Growing at 8.5% CAGR as AI-Powered Diagnostics Expand: New Report by Wissen Research

SHERIDAN, Wyo., Sept. 30, 2026 /PRNewswire/ -- The global medical image analysis software market is projected to grow from USD 4.2 billion in 2026 to USD 6.3 billion by 2031, registering a CAGR of 8.5% during the forecast period (2026–2031), according to a new study by Wissen Research.Growth is being driven by rising volumes of CT, MRI, X-ray, ultrasound, and mammography procedures, alongside growing incidence of cancer, cardiovascular disease, and neurological conditions that require repeated,